bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S5 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Distribution of EGFR Mutations
Supplementary Figure S2 from An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Authors: Piro Geny , Carbone Carmine , Cataldo Ivana , Di Nicolantonio Federica , Giacopuzzi Simone , Aprile Giuseppe , Simionato Francesca , Boschi Federico , Zanotto Marco , Mina Maria Mihaela , Santoro Raffaela , Merz Valeria , Sbarbati Andrea , de Manzoni Giovanni , Scarpa Aldo , Tortora Giampaolo , Melisi Davide
Published: April 2023

Western blot analysis was performed to determine the effect of trastuzumab after 24h of treatment in N87-TR cells and their control cell line.
Supplementary Figure S1 from An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Authors: Piro Geny , Carbone Carmine , Cataldo Ivana , Di Nicolantonio Federica , Giacopuzzi Simone , Aprile Giuseppe , Simionato Francesca , Boschi Federico , Zanotto Marco , Mina Maria Mihaela , Santoro Raffaela , Merz Valeria , Sbarbati Andrea , de Manzoni Giovanni , Scarpa Aldo , Tortora Giampaolo , Melisi Davide
Published: April 2023

Trastuzumab-resistant cells showing features of malignant progression.
Supplementary Figure S1 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Mean RAS Mutant Allele Frequency by Response Category
Supplemental figure legends from Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Authors: Sun Haibo , Lin De-Chen , Cao Qi , Pang Brendan , Gae David D. , Lee Victor Kwan Min , Lim Huey Jin , Doan Ngan , Said Jonathan W. , Gery Sigal , Chow Marilynn , Mayakonda Anand , Forscher Charles , Tyner Jeffrey W. , Koeffler H. Phillip
Published: April 2023

Supplemental figure legends for Figures S1-S5.
Supplemental Tables S1-S9 from Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Authors: Sun Haibo , Lin De-Chen , Cao Qi , Pang Brendan , Gae David D. , Lee Victor Kwan Min , Lim Huey Jin , Doan Ngan , Said Jonathan W. , Gery Sigal , Chow Marilynn , Mayakonda Anand , Forscher Charles , Tyner Jeffrey W. , Koeffler H. Phillip
Published: April 2023

Table S1. Small molecule inhibitors. Listing of all 116 agents on the screening inhibitor panel with respective molecular targets and sources Table S2. Primers for QRT-PCR and plasmid construction. Table S3. IC50s of 116 small molecule inhibitors in EWS cells. Table S4. IC50s of small molecule inhibitors in other cancer types. Table S5. Patients clinical information and H-score numbers. Table S6. MALAT1 expression among different cancer types ( patient sample tissues from Baird Sarcoma database). Table S6. Overlaps of lists of genes significantly co-downregulated and co-upregulated by SYK inhibitor GS-9973 (SYK i) and SYK knockdown (shSYK) in TC71 cells. Table S7. MALAT1 expression among different cancer types (patient sample tissues from Baird Sarcoma database). Table S8. MALAT1 Expression among different cancer types ( cancer cell lines from CCLE database). Table S9. ChIP-seq data source information.
Supplementary Table. S2 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Details of antibodies used for immunoblotting and immunostaining in tumor xenografts and cell lines.
Supplemental Figures from Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Authors: Sun Haibo , Lin De-Chen , Cao Qi , Pang Brendan , Gae David D. , Lee Victor Kwan Min , Lim Huey Jin , Doan Ngan , Said Jonathan W. , Gery Sigal , Chow Marilynn , Mayakonda Anand , Forscher Charles , Tyner Jeffrey W. , Koeffler H. Phillip
Published: April 2023

Fig. S1. GSEA analysis revealed significant enrichment of gene associated with genomic unstable EWS phenotype (A), cell cycle (B) and NF-κB (C) in SYK knockdown cells, and gene associated with metastasis (D) in cells treated with the SYK inhibitor. Fig. S2. Representative IHC photos of p-SYK expression in TC71 control and shSYK cells. No Ab, no antibody control; NC, scramble shRNA control. Fig. S3. TC71 cells were treated with 4 μmol/L GS-9973 or PRT062607 for 48 h, and cell cycle distribution was analyzed by PI staining. Fig. S4. TC71 and SKES1 cells were infected with control (NC) or sh-MYC lentivirus for 72h, and c-MYC protein level was evaluated by immunoblotting assay. Fig. S5.Total nuclear RNA was immunoprecipitated by the antibody-coated beads (either nonspecific IgG or anti-EZH2 antibody), reverse-transcribed and the cDNA was further amplified by qRT-PCR. Bar graphs displayed the relative MALAT1 levels (Y-axis) in different groups. Protein lysates (input, IgG and anti-EZH2 antibodies) were immunoblotted and probed with anti- EZH2 antibody (lower panel). Data represent mean {plus minus} SD, n=3.
Supplementary Figure. S1 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Tumor and prostate volume and serum-PSA levels directly correlate with tumor growth, regression, and recurrence in CWR22 xenograft model.
Supplementary Figure Legends from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Supplementary Figure Legends
Supplement from Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Authors: Yan Fangrong , Mandrekar Sumithra J. , Yuan Ying
Published: April 2023

Supplementary Data, Supplementary Figures S1-S8, Supplementary Table S1
Supplementary Tables 1-3, Supplementary Figures 1-14 from Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Authors: Giraldo Nicolas A. , Becht Etienne , Vano Yann , Petitprez Florent , Lacroix Laetitia , Validire Pierre , Sanchez-Salas Rafael , Ingels Alexandre , Oudard Stephane , Moatti Audrey , Buttard Benedicte , Bourass Sarah , Germain Claire , Cathelineau Xavier , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Table S1. Demographic and clinical characteristics of the analyzed patients; Table S2. Antibodies and conditions used for the IHC studies; Table S3. List of immune-related genes analyzed by Low Density Array; Figure S1. Gating and data analysis strategy; Figure S2. CD4+ and CD8+ T-cell differentiation in ccRCC TIL, and autologous PBL and RIL; Figure S3. Gap statistics according to the possible number of clusters of TIL phenotype. Optimal cut-off according to firstSEmax method (R package: cluster) is displayed (dotted line); Figure S4. PCA analysis including RIL and TIL phenotype. TIL clusters are displayed; Figure S5. Tumor size according to TIL clusters; Figure S6. Percentages of CD4+TIL expressing AM and InR according to tumor clusters. C1, Cluster1; C2, Cluster2; C3, Cluster3; Figure S7. Percentages of CD8+TIL expressing AM and InR according to tumor clusters. C1, Cluster1; C2, Cluster2; C3, Cluster3; Figure S8. Clonality Index and frequency of top 15 clonotypes in CD8+PD-1+ TIL according to tumor clusters. C1, Cluster1; C2, Cluster2; C3, Cluster3; Figure S9. Corrected P values for the differential gene expression between TIL clusters; Figure S10. Correlation matrix including TLS-related genes and immune cells densities in Immune-activated and Immune-regulated tumors; Figure S11. Percentages of CD4+PBL expressing differentiation markers, AM and InR in healthy controls (HC) and ccRCC-bearing patients; Figure S12. Percentages of CD8+PBL expressing differentiation markers, AM and InR in HC and ccRCC-bearing patients; Figure S13. Percentages of CD4+PBL expressing differentiation markers, AM and InR according to PBL Clusters; Figure S14. Percentages of CD8+PBL expressing differentiation markers, AM and InR according to PBL Clusters.
Supplemental Figure 2 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Authors: Assadipour Yasmine , Zacharakis Nikolaos , Crystal Jessica S. , Prickett Todd D. , Gartner Jared J. , Somerville Robert P.T. , Xu Hui , Black Mary A. , Jia Li , Chinnasamy Harshini , Kriley Isaac , Lu Lily , Wunderlich John R. , Zheng Zhili , Lu Yong-Chen , Robbins Paul F. , Rosenberg Steven A. , Goff Stephanie L. , Feldman Steven A.
Published: April 2023

HLA typing data.
Supplementary Materials from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Authors: Hanker Ariella B. , Garrett Joan T. , Estrada Mónica Valeria , Moore Preston D. , Ericsson Paula González , Koch James P. , Langley Emma , Singh Sharat , Kim Phillip S. , Frampton Garrett M. , Sanford Eric , Owens Philip , Becker Jennifer , Groseclose M. Reid , Castellino Stephen , Joensuu Heikki , Huober Jens , Brase Jan C. , Majjaj Samira , Brohée Sylvain , Venet David , Brown David , Baselga José , Piccart Martine , Sotiriou Christos , Arteaga Carlos L.
Published: April 2023

Supplementary Methods and Supplementary Figure Legends
Supplementary Data from Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2
Authors: Chen Xu , Xie Ruihui , Gu Peng , Huang Ming , Han Jinli , Dong Wen , Xie Weibin , Wang Bo , He Wang , Zhong Guangzheng , Chen Ziyue , Huang Jian , Lin Tianxin
Published: April 2023

Supplementary Data
Supplementary Figures S1-8 from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Authors: Pandzic Tatjana , Larsson Jimmy , He Liqun , Kundu Snehangshu , Ban Kenneth , Akhtar-Ali Muhammad , Hellström Anders R. , Schuh Anna , Clifford Ruth , Blakemore Stuart J. , Strefford Jonathan C. , Baumann Tycho , Lopez-Guillermo Armando , Campo Elias , Ljungström Viktor , Mansouri Larry , Rosenquist Richard , Sjöblom Tobias , Hellström Mats
Published: April 2023

Supplementary Figure S1. schematic illustration of piggyBac transposon and transposase vectors used. PB IR refers to piggyBac inverted repeats. FRT is flippase recognition target. Supplementary Figure S2. Real-time quantitative PCR analysis confirms efficient depletion of BMP2K and DCK. Supplementary Figure S3. TP53 deficient HCT116 cell line exhibits reduced sensitivity to F-ara-A. Supplementary Figure S4. Protein expression following transient transfection of the putative fludarabine resistance genes DCK, NUDCD3, ARID5B and LARS in HCT116 cell line. Supplementary Figure S5. Vemurafinib normalizes the response to F-ara-A in cells expressing V600E mutant BRAF. Supplementary Figure S6. Hierarchical clustering of differentially expressed genes in pools of HG3 cells resistant to fludarabine. Supplementary Figure S7. Increased phosphorylation of ERK in HG3 pool resistant to fludarabine. Supplementary Figure S8. Distribution of mutations in the BRAF gene in CLL.
Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Authors: Ni Haiwen , Shirazi Fazal , Baladandayuthapani Veerabhadran , Lin Heather , Kuiatse Isere , Wang Hua , Jones Richard J. , Berkova Zuzana , Hitoshi Yasumichi , Ansell Stephen M. , Treon Steven P. , Thomas Sheeba K. , Lee Hans C. , Wang Zhiqiang , Davis R. Eric , Orlowski Robert Z.
Published: April 2023

Supplementary Table 1. Gene set enrichment analysis* of the impact of exposing WaldenstrÃ¶m's cell lines to R191 with a focus on Akt. Supplementary Table 2. Combination index analysis of R191-based regimens in cell line models of WaldenstrÃ¶m's after a 24 hour treatment.
Supplementary Tables from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Mateo Joaquin , Ganji Gopinath , Lemech Charlotte , Burris Howard A. , Han Sae-Won , Swales Karen , Decordova Shaun , DeYoung M. Phillip , Smith Deborah A. , Kalyana-Sundaram Shanker , Wu Jiuhua , Motwani Monica , Kumar Rakesh , Tolson Jerry M. , Rha Sun Young , Chung Hyun Cheol , Eder Joseph P. , Sharma Sunil , Bang Yung-Jue , Infante Jeffrey R. , Yan Li , de Bono Johann S. , Arkenau Hendrik-Tobias
Published: April 2023

Supplementary Table 7: Next-generation sequencing of tumor biopsy samples (see separate Excel file) Supplementary Table 8: Copy number variations for patients with tumor biopsy samples available (see separate Excel file) Supplementary Table 9: Summary of copy number variations as assessed by polymerase chain reaction (see separate Excel file)
Supplementary Figures S1-S6 from Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions
Authors: Pisanic Thomas R. , Cope Leslie M. , Lin Shiou-Fu , Yen Ting-Tai , Athamanolap Pornpat , Asaka Ryoichi , Nakayama Kentaro , Fader Amanda N. , Wang Tza-Huei , Shih Ie-Ming , Wang Tian-Li
Published: April 2023

Supplementary Figures
Supplementary Figure 1 from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Mateo Joaquin , Ganji Gopinath , Lemech Charlotte , Burris Howard A. , Han Sae-Won , Swales Karen , Decordova Shaun , DeYoung M. Phillip , Smith Deborah A. , Kalyana-Sundaram Shanker , Wu Jiuhua , Motwani Monica , Kumar Rakesh , Tolson Jerry M. , Rha Sun Young , Chung Hyun Cheol , Eder Joseph P. , Sharma Sunil , Bang Yung-Jue , Infante Jeffrey R. , Yan Li , de Bono Johann S. , Arkenau Hendrik-Tobias
Published: April 2023

Supplementary Figure 1: Study design
Supplemental data from Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Authors: de Bono Johann S. , De Giorgi Ugo , Rodrigues Daniel Nava , Massard Christophe , Bracarda Sergio , Font Albert , Arranz Arija Jose Angel , Shih Kent C. , Radavoi George Daniel , Xu Na , Chan Wai Y. , Ma Han , Gendreau Steven , Riisnaes Ruth , Patel Premal H. , Maslyar Daniel J. , Jinga Viorel
Published: April 2023

Includes supplementary methods, figures, and tables.
Supplementary Figures 1-6, Supplementary Tables 1-5 from First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Authors: Stein Mark N. , Bertino Joseph R. , Kaufman Howard L. , Mayer Tina , Moss Rebecca , Silk Ann , Chan Nancy , Malhotra Jyoti , Rodriguez Lorna , Aisner Joseph , Aiken Robert D. , Haffty Bruce G. , DiPaola Robert S. , Saunders Tracie , Zloza Andrew , Damare Sherri , Beckett Yasmeen , Yu Bangning , Najmi Saltanat , Gabel Christian , Dickerson Siobhan , Zheng Ling , El-Deiry Wafik S. , Allen Joshua E. , Stogniew Martin , Oster Wolfgang , Mehnert Janice M.
Published: April 2023

'Figure S1: ONC201 doses versus (A) Cmax and (B) AUC determined after the first dose of ONC201.; Figure S2: Covariant analyses of pharmacokinetic parameters; Figure S3: Caspase-cleaved versus total cytokeratin 18 at baseline and 21 days following the first dose of 625mg ONC201 in (A) an ovarian cancer patient (disease progression within 3 weeks) and (B) a prostate cancer patient (stable disease > 20 weeks). Figure S4: Serum TRAIL ELISA assay following the first dose of ONC201; Figure S5: Serum prolactin induction; Figure S6: Serum prolactin induction versus ONC201 exposure; Table S1. Patient demographics with ONC201 administered every three weeks in dose escalation phase and in the expansion phase with ONC201 RP2D.; Table S2: Adverse events occurring on study that were not attributed to ONC201; Table S3: Individual ONC201 pharmacokinetic parameters for patients in the dose escalation phase; Table S4: Select characteristics of patients in the dose escalation phase. Table S5. Clinical responses and pharmacodynamic in the dose escalation phase.'
Supplementary Figure S4 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Supplementary Figure S4: Dynamics of CTCs: Each line corresponds to one or more patients connecting the number of CTCs per 7.5 mL before and after therapy. The width of a line is proportional to the number of patients having the same number of CTCs before as well as after therapy.
Supplementary materials from Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC)
Authors: Abdulghani Junaid , Gokare Prashanth , Gallant Jean-Nicolas , Dicker David , Whitcomb Tiffany , Cooper Timothy , Liao Jiangang , Derr Jonathan , Liu Jing , Goldenberg David , Finnberg Niklas K. , El-Deiry Wafik S.
Published: April 2023

Supplementary materials Material and Methods Supplemental Figure 1: Quantitative assessment of mRNA expression of Mcl-1, RelA and Stat3 in anaplastic thyroid carcinoma (ATC) cell lines and resected ATC's using qRT-PCR. Supplemental Figure 2: Expressions of NFï�«B-p65 and Stat3pY in ATC. Supplemental Figure 3: Assessment of medical and staining parameters relationship to the overall survival (OS) in the ATC cohort. Supplemental Figure 4: Meta analysis of previously published expression profiles on ATC's. Supplemental Figure 5: Model schematic displaying drug synergy from the drug combination of sorafenib/quinacrine through the targeting of expression of anti-apoptotic Mcl-1. Supplemental Figure 6: In vivo optical near-infrared (NIR) imaging of orthotopic xenografts of human ATC cells. Supplemental Figure 7: Serum chemistry indicates lack of apparent toxicity by the S/Q combination. Supplemental Figure 8: Hematology indicates lack of apparent toxicity by the S/Q combination. Supplemental Figure 9: Reduced surface occupancy of CD34-positive small vessel endothelium and VEGF-expression in 8505C tumor xenografts treated with the combination of sorafenib and quinacrine.
Supplementary Figure S2 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Supplementary Figure S2: Kaplan Meier plots by pathologic complete response (pCR) and CTCs detected after NT. (A, B) DFS, analysis of the whole patient cohort at cut-off {greater than or equal to}1 (A) CTC/7.5 mL and {greater than or equal to}2 (B) CTCs/7.5 mL blood, (C, D) OS, analysis of the whole patient cohort at cut-off {greater than or equal to}1 (C) CTC/7.5 mL and {greater than or equal to}2 (D) CTCs/7.5 mL blood.
Supplementary Tables from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Authors: Pitroda Sean P. , Bao Riyue , Andrade Jorge , Weichselbaum Ralph R. , Connell Philip P.
Published: April 2023

This file includes Supplementary Tables S1-S5. Table S1: Eligible neoadjuvant chemotherapy breast cancer datasets. Table S2: Reference breast cancer datasets for gene expression normalization. Table S3: List of duplicate samples excluded from study. Table S4: Test characteristics of a reduced gene model. Table S5: RPS values for study patients.
Table S1 from EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Authors: Jorge Susan E. , Lucena-Araujo Antonio R. , Yasuda Hiroyuki , Piotrowska Zofia , Oxnard Geoffrey R. , Rangachari Deepa , Huberman Mark S. , Sequist Lecia V. , Kobayashi Susumu S. , Costa Daniel B.
Published: April 2023

Supp Table 1
Supplementary Tables from Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity
Authors: Johnson Steven E. , Ugolkov Andrey , Haney Chad R. , Bondarenko Gennadiy , Li Lin , Waters Emily A. , Bergan Raymond , Tran Andy , O'Halloran Thomas V. , Mazar Andrew , Zhao Ming
Published: April 2023

supplementary Tables
Figure S1 from EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Authors: Jorge Susan E. , Lucena-Araujo Antonio R. , Yasuda Hiroyuki , Piotrowska Zofia , Oxnard Geoffrey R. , Rangachari Deepa , Huberman Mark S. , Sequist Lecia V. , Kobayashi Susumu S. , Costa Daniel B.
Published: April 2023

Supp Fig 1
Figure S5 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

p-p70S6K, pS6 and p-ERK expression in bladder cancer cells treated with pictilisib
Supplementary Data Figure 4 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

Androgen stimulation has limited effect on HSD17B2 mRNA level.
Figure S1 from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

Validation of that PAPSS1 expression is associated with cisplatin sensitivity in lung adenocarcinoma cell lines
Supplementary Table S7 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S7. Effect of low expression of some genes located at 1q or 19q on survival of neuroblastoma patients according to different datasets in R2 database
Supplementary Table 7 from Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Authors: Le Xiuning , Puri Sonam , Negrao Marcelo V. , Nilsson Monique B. , Robichaux Jacqulyne , Boyle Theresa , Hicks J. Kevin , Lovinger Katherine L. , Roarty Emily , Rinsurongkawong Waree , Tang Ming , Sun Huiying , Elamin Yasir , Lacerda Lara C. , Lewis Jeff , Roth Jack A. , Swisher Stephen G. , Lee J. Jack , William William N. , Glisson Bonnie S. , Zhang Jianjun , Papadimitrakopoulou Vassiliki A. , Gray Jhanelle E. , Heymach John V.
Published: April 2023

Platform-match 18 cases
Supplementary Table S5 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S5. Presence of 1q, 19q, and ATRX deletions in samples of patients with these aberrations
Supplementary Table 2 from Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Authors: Le Xiuning , Puri Sonam , Negrao Marcelo V. , Nilsson Monique B. , Robichaux Jacqulyne , Boyle Theresa , Hicks J. Kevin , Lovinger Katherine L. , Roarty Emily , Rinsurongkawong Waree , Tang Ming , Sun Huiying , Elamin Yasir , Lacerda Lara C. , Lewis Jeff , Roth Jack A. , Swisher Stephen G. , Lee J. Jack , William William N. , Glisson Bonnie S. , Zhang Jianjun , Papadimitrakopoulou Vassiliki A. , Gray Jhanelle E. , Heymach John V.
Published: April 2023

Genetic profiling of 42 cases
Supplementary Table S3 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S3. Chromosomal aberrations and corresponding breakpoints and their subclonal frequencies in various samples of the single neuroblastoma patient
Supplemental Figures 1-5 from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Authors: Knudsen Erik S. , Vail Paris , Balaji Uthra , Ngo Hoai , Botros Ihab W. , Makarov Vladimir , Riaz Nadeem , Balachandran Vinod , Leach Steven , Thompson Debrah M. , Chan Timothy A. , Witkiewicz Agnieszka K.
Published: April 2023

Supplemental Figure 1: Clinical and pathological information for the cohort employed in the present study. Supplemental Figure 2: (A) Specific genes that define the immunological signatures as indicated. (B) Application of immunological signatures to TCGA data (n=183 cases) define two principle subtypes as shown by unsuperverised clustering analysis. (C) Interrogation of specific genes by unsupervised clustering analysis in TCGA data (n=183 cases). Supplemental Figure 3: (A) Quantitation of the median survival associated with each of the indicated markers (B) Representative staining of PDL1 expression at the edge of the tumor. The association with overall survival was determined by Kaplan-Meier analysis, and association with stromal type was determined by t-test. **p<0.01. Supplemental Figure 4: (A) Correlation analysis of the indicated immuneregulatory marker gene expression with overall survival. Heatmap depicts Spearman correlation. (B) Correlation values of the indicated gene expression vs. overall survival. *p<0.05, **p<0.01, ***p<0.001. Supplemental Figure 5: (A) Summary of cutpoints utilized in the random-forest clustering of biomarkers. (B) Median survival for each of the random-forest clusters. (C) Summary of the KRAS mutations observed in each cluster.
Supplemental Figure Legends from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Authors: Knudsen Erik S. , Vail Paris , Balaji Uthra , Ngo Hoai , Botros Ihab W. , Makarov Vladimir , Riaz Nadeem , Balachandran Vinod , Leach Steven , Thompson Debrah M. , Chan Timothy A. , Witkiewicz Agnieszka K.
Published: April 2023

Supplemental Figure Legends
Supplementary Tables 1-3, Supplementary Figures 1-5 from Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial–Mesenchymal Transition
Authors: Pang Bo , Wu Nan , Guan Rongwei , Pang Lin , Li Xinlei , Li Su , Tang Liudi , Guo Ying , Chen Jialei , Sun Donglin , Sun Haiming , Dai Jialin , Bai Jing , Ji Guohua , Liu Peng , Liu An , Wang Qiushi , Xiao Sheng , Fu Songbin , Jin Yan
Published: April 2023

Table S1: Primary antibodies used for western blot analysis; Table S2: Univariate and multivariate Cox regression analysis of different prognosis factors in patients with LUAD from TMAS; Table S3: related to Figure 4 and 6. Correlation between expression of RCC2and EMT markers and between expression of RCC2 and p-JNK inLUAD; Supplementary Figure 1. Verifying specificity of anti-RCC2 antibody; Supplementary Figure 2 (related to Figure 1). Kaplan-Meier survival analysis according to RCC2 expression in 204 LUAD patients of GEO dataset(GSE31210) from PrognoScan(log-rank test); Supplementary Figure 3 (related to Figure 4). Representative IHC staining for RCC2, N-cadherin, α-SMA, β-catenin, and E-cadherinin serial sections of patients with LUAD; Supplementary Figure 4 (related to Figure 5). Knockdown of RCC2 suppressed xenograft tumor growth in vivo; Supplementary Figure 5 (related to Figure 6) Representative IHC staining for RCC2 and p-JNK in serial sections of LUAD patients.
Supplemental Table S3. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers
Authors: Kawakami Eiryo , Tabata Junya , Yanaihara Nozomu , Ishikawa Tetsuo , Koseki Keita , Iida Yasushi , Saito Misato , Komazaki Hiromi , Shapiro Jason S. , Goto Chihiro , Akiyama Yuka , Saito Ryosuke , Saito Motoaki , Takano Hirokuni , Yamada Kyosuke , Okamoto Aikou
Published: April 2023

Logistic regression classifiers' normalized coefficient and confidence interval
Supplementary Table S2 from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

Supplementary Table S2 shows the interactions between 2Rs15d and HER2 domain I.
Supplemental Figure S1. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers
Authors: Kawakami Eiryo , Tabata Junya , Yanaihara Nozomu , Ishikawa Tetsuo , Koseki Keita , Iida Yasushi , Saito Misato , Komazaki Hiromi , Shapiro Jason S. , Goto Chihiro , Akiyama Yuka , Saito Ryosuke , Saito Motoaki , Takano Hirokuni , Yamada Kyosuke , Okamoto Aikou
Published: April 2023

Explanation and evaluation of the random forest (RF) classifier. (A) Schematic illustration of the classification of samples by the RF. (B, C) Representative classification trees from the discrimination between malignant and benign tumors. These trees are only representations out of 4,000 trees constructed in the RF classifier. The final class is determined as a result of voting by all 4,000 trees. (D, E) The highest accuracy of prediction (D) and the AUC (E) using different numbers of samples in RF classification between malignant and benign tumors. The mean accuracy and AUC with these 95% confidence intervals were presented for 10 independent sets of randomly selected data of 20%, 40%, 60%, and 80% of patients from the training and test cohorts.
Supplemental Materials and Methods from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

A detailed description of the materials and methods used for the HER2-2Rs15d structure determination, the radioiodination of sdAbs, and all flow cytometry experiments.
Figure S7 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

The combination of AZD9291 with a MEK inhibitor effectively induces apoptosis in AZD9291-resistant NSCLC cell lines
Supplementary Table 3 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Authors: Hertz Daniel L. , Owzar Kouros , Lessans Sherrie , Wing Claudia , Jiang Chen , Kelly William Kevin , Patel Jai , Halabi Susan , Furukawa Yoichi , Wheeler Heather E. , Sibley Alexander B. , Lassiter Cameron , Weisman Lois , Watson Dorothy , Krens Stefanie D. , Mulkey Flora , Renn Cynthia L. , Small Eric J. , Febbo Phillip G. , Shterev Ivo , Kroetz Deanna L. , Friedman Paula N. , Mahoney John F. , Carducci Michael A. , Kelley Michael J. , Nakamura Yusuke , Kubo Michiaki , Dorsey Susan G. , Dolan M. Eileen , Morris Michael J. , Ratain Mark J. , McLeod Howard L.
Published: April 2023

Most Highly Enriched Canonical Pathways
Figure S5 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

The combination of AZD9291 with a MEK inhibitor effectively inhibits the growth of AZD9291-resistant NSCLC cell lines
Supplementary Table 2 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Authors: Hertz Daniel L. , Owzar Kouros , Lessans Sherrie , Wing Claudia , Jiang Chen , Kelly William Kevin , Patel Jai , Halabi Susan , Furukawa Yoichi , Wheeler Heather E. , Sibley Alexander B. , Lassiter Cameron , Weisman Lois , Watson Dorothy , Krens Stefanie D. , Mulkey Flora , Renn Cynthia L. , Small Eric J. , Febbo Phillip G. , Shterev Ivo , Kroetz Deanna L. , Friedman Paula N. , Mahoney John F. , Carducci Michael A. , Kelley Michael J. , Nakamura Yusuke , Kubo Michiaki , Dorsey Susan G. , Dolan M. Eileen , Morris Michael J. , Ratain Mark J. , McLeod Howard L.
Published: April 2023

1000 SNPs with greatest statistical association with cumulative docetaxel dose at grade 3+ neuropathy in CALGB 90401 discovery GWAS.
Figure S3 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

Effects of AZD9291 on modulating Bim and Mcl-1 levels in parental HCC827 (A) and AZD9291-resistant HCC827 cells (B).
Supplementary Figure 3: VAC14 Heterozygous Mice are Sensitive to Nociceptive Stimuli from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Authors: Hertz Daniel L. , Owzar Kouros , Lessans Sherrie , Wing Claudia , Jiang Chen , Kelly William Kevin , Patel Jai , Halabi Susan , Furukawa Yoichi , Wheeler Heather E. , Sibley Alexander B. , Lassiter Cameron , Weisman Lois , Watson Dorothy , Krens Stefanie D. , Mulkey Flora , Renn Cynthia L. , Small Eric J. , Febbo Phillip G. , Shterev Ivo , Kroetz Deanna L. , Friedman Paula N. , Mahoney John F. , Carducci Michael A. , Kelley Michael J. , Nakamura Yusuke , Kubo Michiaki , Dorsey Susan G. , Dolan M. Eileen , Morris Michael J. , Ratain Mark J. , McLeod Howard L.
Published: April 2023

Sensitivity to mechanical stimuli with Von Frey filaments for C57BL/6J mice and litter-mates heterozygous for VAC14 prior to docetaxel treatment. The figure displays the estimate of the proportion of mice without a hind-paw withdrawal response to stimulation by each Von Frey fiber weight, e.g., no mice respond to fibers {less than or equal to}0.2 g and all mice respond to fibers{greater than or equal to}1.4 g. The VAC14 heterozygous mice (hatched line) are more likely than wild-type mice (solid line) to respond, meaning they are more sensitive to nociceptive stimuli (p=0.0012). Gray lines denote 95% confidence intervals.
Supplementary Figure 1: Patient Disposition from Clinical Trial to Pharmacogenetic Analysis from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Authors: Hertz Daniel L. , Owzar Kouros , Lessans Sherrie , Wing Claudia , Jiang Chen , Kelly William Kevin , Patel Jai , Halabi Susan , Furukawa Yoichi , Wheeler Heather E. , Sibley Alexander B. , Lassiter Cameron , Weisman Lois , Watson Dorothy , Krens Stefanie D. , Mulkey Flora , Renn Cynthia L. , Small Eric J. , Febbo Phillip G. , Shterev Ivo , Kroetz Deanna L. , Friedman Paula N. , Mahoney John F. , Carducci Michael A. , Kelley Michael J. , Nakamura Yusuke , Kubo Michiaki , Dorsey Susan G. , Dolan M. Eileen , Morris Michael J. , Ratain Mark J. , McLeod Howard L.
Published: April 2023

CONSORT diagram illustrating patient flow from enrollment on parent study to population included in pharmacogenetic discovery analysis and quality control filtering of SNPs from the Illumina HumanHap610-Quad into the pharmacogenetic analysis.
Supplemental Table 1 from Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer
Authors: Hamilton Duane H. , Griner Lesley Mathews , Keller Jonathan M. , Hu Xin , Southall Noel , Marugan Juan , David Justin M. , Ferrer Marc , Palena Claudia
Published: April 2023

Pixel analysis of immunohistochemical staining of various markers in tumor xenografts shown in Figure 6.
Supplementary Table S4 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S4: Pathway analysis of genes with mutations enriched in the metastasis or associated with loss of heterozygosity (LOH) in the metastasis using Ingenuity Pathway Analysis and g:Profiler.
Supplemental Figure 1 from Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer
Authors: Hamilton Duane H. , Griner Lesley Mathews , Keller Jonathan M. , Hu Xin , Southall Noel , Marugan Juan , David Justin M. , Ferrer Marc , Palena Claudia
Published: April 2023

Validation of immunohistochemistry staining method for estrogen receptor 1.
Supplementary Table S2 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S2: Genomic analyses performed for the samples analyzed in the study and validation rates of mutations identified by wholeâ€�exome sequencing and Validation of mutations identified by wholeâ€�exome sequencing using targeted sequencing and amplicon sequencing.
Table S3 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Table 3 | Binomial testing of kinome sequencing variants.
Supplementary Data from A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Authors: Trefny Marcel P. , Rothschild Sacha I. , Uhlenbrock Franziska , Rieder Dietmar , Kasenda Benjamin , Stanczak Michal A. , Berner Fiamma , Kashyap Abhishek S. , Kaiser Monika , Herzig Petra , Poechtrager Severin , Thommen Daniela S. , Geier Florian , Savic Spasenija , Jermann Philip , Alborelli Ilaria , Schaub Stefan , Stenner Frank , Früh Martin , Trajanoski Zlatko , Flatz Lukas , Mertz Kirsten D. , Zippelius Alfred , Läubli Heinz
Published: April 2023

Supplementary Methods and Data
Supplementary figures and tables legends from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Legends of supplementary figures and tables
Supplementary Methods from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Methods file
Supplemental Materials and Methods from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

Supplemental Materials and Methods: real time PCR, immunostaining, Western blotting, ADAM17 activity; Supplemental references for supplemental Methods Supplemental Figure Legends; Supplemental Table 1: real time PCR primer sequences
Supplementary table 1 from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Authors: Liu Mingyang , Yang Jingxuan , Zhang Yuqing , Zhou Zhijun , Cui Xiaobo , Zhang Liyang , Fung Kar-Ming , Zheng Wei , Allard Felicia D. , Yee Eric U. , Ding Kai , Wu Huanwen , Liang Zhiyong , Zheng Lei , Fernandez-Zapico Martin E. , Li Yi-Ping , Bronze Michael S. , Morris Katherine T. , Postier Russell G. , Houchen Courtney W. , Yang Jing , Li Min
Published: April 2023

Supplementary table 1 showed the clinic-pathological data of patients with pancreatic adenocarcinoma.
Supplementary figures from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Authors: Liu Mingyang , Yang Jingxuan , Zhang Yuqing , Zhou Zhijun , Cui Xiaobo , Zhang Liyang , Fung Kar-Ming , Zheng Wei , Allard Felicia D. , Yee Eric U. , Ding Kai , Wu Huanwen , Liang Zhiyong , Zheng Lei , Fernandez-Zapico Martin E. , Li Yi-Ping , Bronze Michael S. , Morris Katherine T. , Postier Russell G. , Houchen Courtney W. , Yang Jing , Li Min
Published: April 2023

Supplementary Figure 1. ZIP4 is correlated with EMT markers in pancreatic cancer tissue of KPC mice. Supplementary Figure 2. Knocking down ZIP4 upregulated ZO-1 and claudin-1 expression in pancreatic cancer. Supplementary Figure 3. Knocking down ZIP4 regulated mRNA of EMT markers in pancreatic cancer cell lines. Supplementary Figure 4. ZIP4 repressed ZO-1 and claudin-1 is independent with CREB. Supplementary Figure 5. Knocking down efficiency of ZO-1 and claudin-1 in AsPC-shZIP4 cells.
Supplementary Figure S3 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S3. Flowchart of data acquisition for metabolites after unbiased metabolomics and lipidomics.
Table S2 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

Primary renal tumor response on sunitinib according to MSKCC risk group
Supplemental legend from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplemental legend